Efficacy Study of Rituximab After ASCT in High-Risk Diffuse Large B-Cell Lymphoma

NCT00169169 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

430

Enrollment

OTHER

Sponsor class

Conditions

CD20-Positive Large B-Cell Lymphoma

Interventions

DRUG: ACVBP
DRUG: ACE
DRUG: rituximab
PROCEDURE: Autologous stem cell transplant

Sponsor

Lymphoma Study Association